...
【24h】

Role of the endocytic pathway in carcinogenesis.

机译:内吞途径在致癌作用中的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

This commentary was prompted by many reports that carcinogenesis involving various carcinogens and various types of systems is blocked by inhibitors of endolysosomal proteases (i.e. leupeptin, antipain). These findings have been largely ignored by cancer investigators so far. In this commentary based on these reports a carcinogenesis model is suggested that does not involve direct attack by the carcinogen onto target cell DNA. This model proposes the following steps in the initial phase of carcinogenesis: interaction of a carcinogen with an appropriate cell surface receptor (i.e. possibly the receptor for the epidermal growth factor). This carcinogen-receptor complex is endocytosed and fragmented by various cathepsins to form small peptides (i.e. di-and tripeptides) some of which enter the nucleus and interact very specifically with the protein repressors that normally (during G0 phase) inhibit expression of oncogenes critical to the transformation process. This interaction causes removal of the repressors from these oncogenes. The oncogenes, freed from their repressors are then expressed, culminating in carcinogenesis. This then defines the G0/G1 transition comprising the initial phases of carcinogenesis. Note is taken of reports that the only cells transformed in a heterogeneous collection of cells comprising target organs are in the G0 stem cell subpopulation. The need for such an alternative mechanism is outlined in terms of reports that major kinases (i.e. MAPK and PI3K) operate only after entry into cell cycle (during G1). Thus an answer is provided as to what events occur before entry into cell cycle, the events that define the transition from G0 to G1. In addition, note it taken of the recent reports that suggest that epigenetic mechanisms operate in the carcinogenic process and an attempt is made to harmonize the model presented in this commentary with epigenetic mechanisms as proposed in recent years.
机译:许多报道提示这一评论是,涉及内在的溶酶体蛋白酶(如亮肽素,抗痛药)抑制剂阻止了涉及多种致癌物和多种类型系统的致癌作用。迄今为止,这些发现已被癌症研究者广泛忽略。在基于这些报道的评论中,提出了一种致癌模型,该模型不涉及致癌物对靶细胞DNA的直接攻击。该模型提出了在致癌作用初始阶段的以下步骤:致癌物与适当的细胞表面受体(即可能是表皮生长因子的受体)的相互作用。该致癌物受体复合物被各种组织蛋白酶内吞并破碎,形成小肽(即二肽和三肽),其中一些进入细胞核并与通常在G0期抑制蛋白表达的蛋白阻抑物相互作用非常特异性。转型过程。这种相互作用导致从这些癌基因中去除阻遏物。然后表达从其阻遏物释放出来的致癌基因,最终致癌。然后定义了G0 / G1过渡,包括癌变的初始阶段。需要注意的是,在包含靶器官的异质细胞集合中转化的唯一细胞是在G0干细胞亚群中。对于这样一种替代机制的需求,据报道主要激酶(即MAPK和PI3K)仅在进入细胞周期后(在G1期间)才起作用。因此,提供了关于进入细胞周期之前发生了什么事件的答案,这些事件定义了从G0到G1的转变。此外,请注意最近的报告,这些报告表明表观遗传机制在致癌过程中起作用,并且试图将本评论中提出的模型与近年来提出的表观遗传机制相协调。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号